Parathyroid hormone (1–84): new clinical perspectives for treating patients at high-risk of fractures

References

• Poole KE, Compston JE. Osteoporosis and its management. Br. Med. J.333, 1251–1256 (2006).
   PubMed Web of Science ®Google Scholar
• Compston JE. Recombinant parathyroid hormone in the management of osteoporosis. Calcif. Tissue Int.77, 65–71 (2005).
   PubMedGoogle Scholar
• Neer RM, Arnaud CD, Zanchetta JR et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med.344, 1434–1441 (2001).
   PubMed Web of Science ®Google Scholar
• Potts JT. Parathyroid hormone: past and present. J. Endocrinol.187, 311–325 (2005).
   PubMed Web of Science ®Google Scholar
• Brown EM, Jüppner H. Parathyroid hormone: synthesis, secretion and action. In: Primer on the Metabolic Bone Diseases and Disorders of Bone Metabolism, Sixth edition. Favus MJ (Ed.). American Society for Bone and Mineral Research, Washington, DC, USA 90–106 (2006).
   Google Scholar
• Onyia JE, Helvering LM, Gelbert L et al. Molecular profile of catabolic versus anabolic treatment regimens of parathyroid hormone (PTH) in rat bone: an analysis by DNA microarray. J. Cell Biochem.95, 403–418 (2005).
   PubMedGoogle Scholar
• Locklin RM, Khosla S, Turner RT, Riggs BL 2003 Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J. Cell Biochem.89, 180–190 (2003).
   PubMed Web of Science ®Google Scholar
• Ma YL, Zeng Q, Donley DW et al. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J. Bone Miner. Res.21, 855–864 (2006).
   PubMed Web of Science ®Google Scholar
• Huang JC, Sakata T, Pfleger LL et al. PTH differentially regulates expression of RANKL and OPG. J. Bone Miner. Res.19, 235–244 (2004).
   PubMed Web of Science ®Google Scholar
• von Stechow D, Zurakowski D, Pettit AR et al. Differential transcriptional effects of PTH and estrogen during anabolic bone formation. J. Cell Biochem.93, 476–490 (2004).
   PubMedGoogle Scholar
• Kulkarni NH, Halladay DL, Miles RR et al. Effects of parathyroid hormone on Wnt signaling pathway in bone. J. Cell Biochem.95, 1178–1190 (2005).
   PubMedGoogle Scholar
• Tobimatsu T, Kaji H, Sowa H et al. Parathyroid hormone increases β-catenin levels through Smad3 in mouse osteoblastic cells. Endocrinology147, 2583–2590 (2006).
   PubMed Web of Science ®Google Scholar
• Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone37, 148–158 (2005).
   PubMed Web of Science ®Google Scholar
• Bellido T, Ali AA, Plotkin LI et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. J. Biol. Chem.278, 50259–50272 (2003).
   PubMed Web of Science ®Google Scholar
• Schwietert HR, Groen EWJ, Sollie FAE, Jonkman JH. Single-dose subcutaneous administration of recombinant parathyroid hormone (rPTH [1–84] in healthy postmenopausal volunteers. Clin. Pharmacol. Ther.61, 360–376 (1997).
   PubMedGoogle Scholar
• Hodsman AB, Hanley DA, Ettinger MP et al. Efficacy and safety of human parathyroid hormone-(1–84) in increasing bone mineral density in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab.88, 5212–5220 (2003).
   PubMed Web of Science ®Google Scholar
• Kimmel DB, Bozzato RP, Kronis KA et al. The effect of recombinant human (1–84) or synthetic human (1–34) parathyroid hormone on the skeleton of adult osteopenic ovariectomised rates. Endocrinology132, 1577–1584 (1993).
   PubMed Web of Science ®Google Scholar
• Whitfield JF, Morley P, Willick GE et al. Comparison of the ability of recombinant human parathyroid hormone, rhPTH-(1–84), and hPTH-(1–31)NH2 to stimulate femoral trabecular bone growth in ovariectomised rats. Calcif. Tissue Int.60, 26–29 (1997).
   PubMed Web of Science ®Google Scholar
• Ejersted C, Andreassen TT, Oxlund H et al. Human parathyroid hormone (1–34) and (1–84) increase the mechanical strength and thickness of cortical bone in rats. J. Bone Miner. Res.8, 1097–1010 (1993).
   PubMedGoogle Scholar
• Samnegard E, Iwaniec UT, Cullen DM, Kimmel DB, Recker RR. Maintenance of cortical bone in human parathyroid hormone (1–84)-treated ovariectomised rats. Bone28, 251–260 (2001).
   PubMedGoogle Scholar
• Moreau IA, Smith SY, Guldberg RE, Turner CH, Newman MK, Fox J. Treatment of osteopenic rhesus monkeys with parathyroid hormone 1–84 for 16 months improves vertebral trabecular bone quantity and quality. J. Bone Miner. Res.20(Suppl. 1), S412 (2005).
   Google Scholar
• Dempster DW, Cosman F, Kurland ES et al. Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone Miner. Res.16, 1846–1853 (2001).
   PubMed Web of Science ®Google Scholar
• Lindsay R, Cosman F, Zhou H et al. A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest biopsy: early actions of teriparatide. J. Bone Miner. Res.21, 366–373 (2006).
   PubMed Web of Science ®Google Scholar
• Compston JE. Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone40(6), 1447-52 (2007).
   PubMed Web of Science ®Google Scholar
• Preotact®, product information. Full-length parathyroid hormone, Nycomed UK, Ltd, EU (Online) (2006).
   Google Scholar
• Vahle JL, Sato M, Long GG et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1–34) for 2 years and relevance to human safety. Toxicol. Pathol.30, 312–321 (2002).
   PubMed Web of Science ®Google Scholar
• Jolette J, Wilker CE, Smith SY et al. Defining a non-carcinogenic dose of recombinant human parathyroid hormone 1–84 in a 2-yr study in Fischer 344 rats. Toxicol. Pathol.34, 929–940 (2006).
   PubMed Web of Science ®Google Scholar
• Preotact. Summary of Product Characteristics (2006).
   Google Scholar
• Greenspan SL, Bone HG, Ettinger MP et al. Effect of recombinant human parathyroid hormone (1–84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann. Intern. Med.146, 326–339 (2007).
   PubMed Web of Science ®Google Scholar
• Bogado C, Zanchetta JR, Gordon CL et al. Treatment of postmenopausal osteoporotic women with parathyroid hormone (1–84) for 18 months decreases BMD but does not affect indices of bone strength at the distal radius. J. Bone Miner. Res.21(Suppl. 1), S112 (2006).
   Google Scholar
• Bogado C, Zanchetta JR, Mango A, Mathisen AL, Fox J, Newman MK. Effects of parathyroid hormone 1–84 on cortical and trabecular bone at the hip as assessed by QCT: results at 18 months from the TOP Study. J. Bone Miner. Res.20(Suppl. 1), S22 (2005).
   Web of Science ®Google Scholar
• Greenspan SL, Hanley DA, Morris SA, Marriott TB. Bone turnover markers and BMD remain elevated in postmenopausal osteoporotic women through a full 24 months of treatment with human parathyroid hormone 1–84 (PTH). J. Bone Miner. Res.21(Suppl. 1), S114 (2006).
   Google Scholar
• Black DM, Greenspan SL, Ensrud KE et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N. Engl. J. Med.349, 1207–1215 (2003).
   PubMed Web of Science ®Google Scholar
• Black DM, Bilezekian JP, Ensrud KE et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. New Engl. J. Med.353, 555–565 (2005).
   PubMed Web of Science ®Google Scholar
• Fogelman I, Christiansen C, Spector T, Fraser WD, Fordham J. Safety and efficacy of PTH(1–84) at 18 and 24 months in women with postmenopausal osteoporosis receiving hormone therapy: results from the POWER study. J. Bone Miner. Res.20(Suppl. 1), S21–S22 (2005).
   Google Scholar
• Black D, Thompson D, Quandt SA, Palermo L, Ensrud K, Johnell O. Alendronate reduces risk of vertebral fracture in women with BMD T-scores above -2.5: results from the fracture intervention trial (FIT). Osteoporos. Int.13(Suppl. 1), S27 (2002).
   Google Scholar
• Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. A randomized controlled trial. JAMA282, 1344–1352 (1999).
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos. Int.11, 83–91 (2000).
   PubMed Web of Science ®Google Scholar
• Chesnut CH, Skag A, Christiansen C et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res.19, 1241–1249 (2004).
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA282, 637–645 (1999).
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E et al. The effect of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N. Engl. J. Med.350, 459–468 (2004).
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356, 1809–1822 (2007).
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N. Engl. J. Med.344, 333–340 (2001)
   PubMed Web of Science ®Google Scholar
• Reginster J-Y, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J. Clin. Endocrinol. Metab.90, 2816–2822 (2005).
   PubMed Web of Science ®Google Scholar
• Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jonsson B. Intervention thresholds for osteoporosis in the UK. Bone36, 22–32 (2005).
   PubMed Web of Science ®Google Scholar
• Compston JE, Seeman E. Compliance with osteoporosis therapy is the weakest link. Lancet368, 973–974 (2006).
   PubMed Web of Science ®Google Scholar
• Seeman E, Compston J, Adachi J et al. Non-compliance: the Achilles’ heel; of anti-fracture efficacy. Osteoporos. Int.18, 711–719 (2007).
   PubMed Web of Science ®Google Scholar
• Compston J. Treatments for osteoporosis - looking beyond the HORIZON. N. Engl. J. Med.356, 1878–1880 (2007).
   PubMedGoogle Scholar
• McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N. Engl. J. Med.354, 821–831 (2006).
   PubMed Web of Science ®Google Scholar